Market Overview:
The global oligonucleotide therapeutics market is expected to reach USD XX million by 2030, at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of various diseases, rising demand for novel therapies, and technological advancements in the field of oligonucleotide therapeutics. Based on type, antisense oligonucleotides accounted for the highest proportion of income in 2018 and are expected to maintain their dominance during the forecast period. This can be attributed to their high efficacy and growing demand as targeted therapies for various diseases. Oligonucleotide therapeutics based on aptamers are also expected to witness significant growth during the forecast period owing to their advantages over traditional antibodies such as high specificity and affinity. Based on application, neuromuscular diseases and hepatic VOD are estimated to account for a majority share of revenue generated by this market during the forecast period. This can be primarily attributedto factors such as increasing prevalenceof these disordersand availabilityof novel therapeutic options based on oligonucleotides.
Product Definition:
Oligonucleotide therapeutics are nucleic acid-based drugs used to treat various diseases. Oligonucleotides can be delivered intravenously, orally, or topically. They are important because they can specifically target and modulate the expression of genes implicated in disease.
Antisense Oligonucleotide:
Antisense oligonucleotide is an artificial nucleic acid, which is capable of blocking the action of natural genes. These molecules are created by joining a short sequence of DNA ( usually 20 - 30 bases) with an amino acid chain at one end and a phosphate group at the other end. The molecule has RNA-like properties but does not code for any protein; it functions only as a genetic switch that controls gene expression.
Aptamer:
Aptamers are short, linear molecules (~20-30 kDa) that can bind to a wide variety of ligands. They are naturally occurring biologics and have been extensively studied in the past few years due to their potential therapeutic value. Aptamers hold great potential for treating various diseases as they exhibit greater efficacy than conventional drugs with similar molecular weights.
Application Insights:
The other application segment includes oncology, infectious diseases, cardiovascular and respiratory diseases. Other oligonucleotide therapeutics include antisense therapeutics, aptamers and others. In 2018, the other segment accounted for a lower proportion of income in comparison to the hepatic VOD and ATTR applications. However, this is expected to change over the forecast period as these are growing applications that offer various benefits such as reduced drug toxicity & adverse effects & improved efficacy/speed of action than conventional nucleic acid drugs., The use of oligonucleotides for treating cancer has increased significantly over recent years due to their ability to induce cell death in tumor cells without affecting healthy cells., According to an article published by NCBI in 2017.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The presence of a large number of clinical trialists and CROs that assist with drug development is one factor responsible for its continued dominance. Moreover, the high cost associated with drug development and extensive R&D undertaken by major players are also contributing to its growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure, rising disposable income levels, and an increase in disease prevalence rates especially cancer & neurological disorders due to environmental triggers such as smoking & alcohol consumption which result in genomic instability leading to generation of mutations thus increasing susceptibility towards diseases (Choubey et al., 2016). In addition, growing awareness regarding early diagnosis will further boost regional market growth during the forecast period.
Growth Factors:
- Increasing demand for targeted therapeutics: The increasing prevalence of cancer and other diseases is driving the demand for targeted therapeutics such as oligonucleotide therapies. This is because these therapies are designed to specifically target the underlying cause of the disease, thereby reducing the potential side effects associated with traditional treatments.
- Growing investment in R&D: Pharmaceutical companies are investing heavily in R&D to develop new and improved oligonucleotide therapies. This is helping to drive innovation and growth in the market.
- Rising number of clinical trials: A growing number of clinical trials are being conducted on oligonucleotide therapies, which is helping to improve their efficacy and safety profile. This is attracting more investors to this segment of the market, thereby fuelling its growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oligonucleotide Therapeutics Market Research Report
By Type
Antisense Oligonucleotide, Aptamer, Other, In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%., Oligonucleotide Therapeutic
By Application
Neuromuscular Diseases, ATTR, Hepatic VOD, Other, According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
By Companies
Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics, Oligonucleotide Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Oligonucleotide Therapeutics Market Report Segments:
The global Oligonucleotide Therapeutics market is segmented on the basis of:
Types
Antisense Oligonucleotide, Aptamer, Other, In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%., Oligonucleotide Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Neuromuscular Diseases, ATTR, Hepatic VOD, Other, According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Sarepta Therapeutics
- Jazz Pharmaceuticals
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Dynavax Technologies
- Kastle therapeutics
- Akcea Therapeutics
- Oligonucleotide Therapeutic
Highlights of The Oligonucleotide Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antisense Oligonucleotide
- Aptamer
- Other
- In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
- Oligonucleotide Therapeutic
- By Application:
- Neuromuscular Diseases
- ATTR
- Hepatic VOD
- Other
- According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oligonucleotide Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oligonucleotide therapeutics are a type of drug that uses oligonucleotides as their active ingredient. These drugs are used to treat diseases and conditions by targeting specific genes or proteins.
Some of the key players operating in the oligonucleotide therapeutics market are Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics, Oligonucleotide Therapeutic.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oligonucleotide Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oligonucleotide Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oligonucleotide Therapeutics Market - Supply Chain
4.5. Global Oligonucleotide Therapeutics Market Forecast
4.5.1. Oligonucleotide Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oligonucleotide Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oligonucleotide Therapeutics Market Absolute $ Opportunity
5. Global Oligonucleotide Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
5.3.1. Antisense Oligonucleotide
5.3.2. Aptamer
5.3.3. Other
5.3.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
5.3.5. Oligonucleotide Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oligonucleotide Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
6.3.1. Neuromuscular Diseases
6.3.2. ATTR
6.3.3. Hepatic VOD
6.3.4. Other
6.3.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oligonucleotide Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oligonucleotide Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oligonucleotide Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oligonucleotide Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oligonucleotide Therapeutics Demand Share Forecast, 2019-2026
9. North America Oligonucleotide Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oligonucleotide Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
9.4.1. Neuromuscular Diseases
9.4.2. ATTR
9.4.3. Hepatic VOD
9.4.4. Other
9.4.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
9.7.1. Antisense Oligonucleotide
9.7.2. Aptamer
9.7.3. Other
9.7.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
9.7.5. Oligonucleotide Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oligonucleotide Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Oligonucleotide Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oligonucleotide Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
10.4.1. Neuromuscular Diseases
10.4.2. ATTR
10.4.3. Hepatic VOD
10.4.4. Other
10.4.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
10.7.1. Antisense Oligonucleotide
10.7.2. Aptamer
10.7.3. Other
10.7.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
10.7.5. Oligonucleotide Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oligonucleotide Therapeutics Demand Share Forecast, 2019-2026
11. Europe Oligonucleotide Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oligonucleotide Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
11.4.1. Neuromuscular Diseases
11.4.2. ATTR
11.4.3. Hepatic VOD
11.4.4. Other
11.4.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
11.7.1. Antisense Oligonucleotide
11.7.2. Aptamer
11.7.3. Other
11.7.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
11.7.5. Oligonucleotide Therapeutic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oligonucleotide Therapeutics Demand Share, 2019-2026
12. Asia Pacific Oligonucleotide Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oligonucleotide Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
12.4.1. Neuromuscular Diseases
12.4.2. ATTR
12.4.3. Hepatic VOD
12.4.4. Other
12.4.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
12.7.1. Antisense Oligonucleotide
12.7.2. Aptamer
12.7.3. Other
12.7.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
12.7.5. Oligonucleotide Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oligonucleotide Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Oligonucleotide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oligonucleotide Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oligonucleotide Therapeutics Market Size and Volume Forecast by Application
13.4.1. Neuromuscular Diseases
13.4.2. ATTR
13.4.3. Hepatic VOD
13.4.4. Other
13.4.5. According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oligonucleotide Therapeutics Market Size and Volume Forecast by Type
13.7.1. Antisense Oligonucleotide
13.7.2. Aptamer
13.7.3. Other
13.7.4. In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
13.7.5. Oligonucleotide Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oligonucleotide Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oligonucleotide Therapeutics Market: Market Share Analysis
14.2. Oligonucleotide Therapeutics Distributors and Customers
14.3. Oligonucleotide Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biogen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sarepta Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Jazz Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bausch & Lomb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Alnylam Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Dynavax Technologies
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kastle therapeutics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Akcea Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Oligonucleotide Therapeutic
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
&nbs